ClinicalTrials.gg
CompletedNCT05051891Updated Mar 31, 2026

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

A Phase 3 interventional study of Orelabrutinib and R-CHOP and R-CHOP in Treatment-naїve Mantle Cell Lymphoma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 22 sites in China. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell — 8 open to participants now, 8 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Mantle-Cell.

Enrollment
10th of 10
3 · median 42
Started
2021
the only one that year
Phase 3
3 of 10
2 open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, this one is the 10th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, and was the 2nd registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

8 of the 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing orelabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naїve mantle cell lymphoma.

03

Conditions studied

  • Treatment-naїve Mantle Cell Lymphoma
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 65 \< age \<80, or 60 ≤ age ≤65 and is ineligible for stem cell transplantation as assessed by the investigator
  2. Histopathological confirmed MCL and either expression of cyclin D1 or t (11;14) chromosomal translocation (in association with CD20). The verification will be based on central review of the local pathology report.
  3. No previous systemic treatment for MCL.
  4. physical strength score is 0-2.
  5. Expected survival time >6 months.
  6. Voluntary written prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled or significant cardiovascular diseases
  2. History of stroke or intracranial hemorrhage within 6 months before first administration of study treatment.
  3. Any mental or cognitive impairments which may limit the subject 's understanding and execution of as well as study compliance;
  4. Pregnant or breastfeeding women and those who do not agree to take measures.
  5. Conditions in which a potentially life-threatening illness or severe organ dysfunction is not considered appropriate by the investigator.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    the experimental group

    Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

    Drug: Orelabrutinib and R-CHOP

  • Experimental
    The control group

    R-CHOP

    Drug: R-CHOP

Interventions

  • DrugOrelabrutinib and R-CHOP

    Drug page: Orelabrutinib

    Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

  • DrugR-CHOP

    Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)

06

What researchers measure

Primary outcomes

  1. PFS

    To evaluate the Progression-free Survival (PFS) by the Independent Review Committee (IRC) according to the 2014 International Working Group Criteria for Non-Hodgkin Lymphoma (iwNHL).

    Time frame: Up to 6 years

Secondary outcomes

  1. ORR

    Objective Response Rate

    Time frame: Up to 6 years

  2. CRR

    Complete Response Rate

    Time frame: Up to 6 years

  3. OS

    Overall Survival

    Time frame: Up to 6 years

07

Study locations

22 sites
  • Anhui Province Cancer Hospital
    Hefei, Anhui 230009, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100143, China
  • Tumor in Hunan Province
    Hunan, Changsha 410013, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 50011, China
  • Henan Tumor Hospital
    Zhengzhou, Henan 450008, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 3300008, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Hospital of China Medical University
    Shenyang, Liaojing 110001, China
  • The First Affiliated Hospital of Guangxi Medical University
    Guangxi, Nanning 530021, China
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
  • West China Hospital,Sichuan University
    Chengdu, Sichuan 610041, China
  • Hospital of Hematology, Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 300052, China
  • Tianjin Cancer Hospital
    Tianjin, Tianjin Municipality 300060, China
  • he First Affiliated Hospital of Zhengjiang University
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jun 2025, 42 months.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Sep 21, 2021
StartActual
Dec 22, 2021
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05051891
Responsible party
Sponsor
First posted
Sep 21, 2021
Start date
Dec 22, 2021
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Last update
Mar 31, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion